Embecta

Embecta Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Embecta (EMBC) as of Nov 11, 2026 is 144.24. In the previous year, Cash Conversion Cycle (CCC) was 137.65 — a change of 4.79% (higher).

Cash Conversion Cycle

144.24

YoY

4.79%

Last updated:

Cash Conversion Cycle (CCC) of Embecta is 2025 144.24 . Cash Conversion Cycle (CCC) of Embecta was 2024 137.65 . It decreases by 4.79% higher compared to the previous year.

The Embecta Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
99.86 USD
Jan 1, 2020
99.11 USD
Jan 1, 2021
111.11 USD
Jan 1, 2022
91.35 USD
Jan 1, 2023
102.86 USD
Jan 1, 2024
137.65 USD
Jan 1, 2025
144.24 USD
The Embecta Cash Conversion Cycle history
YEARCash Conversion CycleYoY
144.24+4.79%
137.65+33.82%
102.86+12.60%
91.35-17.78%
111.11+12.10%
99.11-0.75%
99.86—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Cash Conversion Cycle (CCC) of Embecta is 144.24 in 2025.

Cash Conversion Cycle (CCC) of Embecta changed from 137.65 to 144.24, representing a 4.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Embecta since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Embecta with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Embecta

All Key Metrics — Embecta